Application and Dosimetric Requirements for Gallium-68–labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors

Abstract : Neuroendocrine tumors (NETs) are associated with variable prognosis, with grade 1 and 2 NETs having more favorable outcomes than grade 3. Patients with gastroenteropancreatic (GEP)-NET need individualized interdisciplinary evaluations and treatment. New treatment options have become available with significant improvements in progression-free survival. Peptide receptor radionuclide therapy (PRRT) using (90)Y or (177)Lu-labeled somatostatin analogues (SSTa) has also shown promise in the treatment of advanced progressive NETs. (68)Ga-1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA)-SSTa can be used as companion imaging agents to assist in radionuclide therapy selection. (68)Ga-DOTA-SSTa PET/computed tomography might also provide information for prognosis, tumor response assessment to PRRT, and internal dosimetry.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02329854
Contributeur : Amandine Michel-Avella <>
Soumis le : mercredi 23 octobre 2019 - 17:06:43
Dernière modification le : jeudi 24 octobre 2019 - 01:45:15

Lien texte intégral

Identifiants

Citation

David Taieb, Philippe Garrigue, Manuel Bardiès, Ahmad Esmaeel Abdullah, Karel Pacak. Application and Dosimetric Requirements for Gallium-68–labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics, WB Saunders, 2015, 10 (4), pp.477-486. ⟨10.1016/j.cpet.2015.06.001⟩. ⟨hal-02329854⟩

Partager

Métriques

Consultations de la notice

14